🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

‼️ ARTO Oligomet CRPC (up to 3 non-visceral metastatic lesions) -> 1:1 AAP alone vs AAP + SBRT to all the sites of disease HR for progression of 0.35 (95% CI, 0.21 to 0.57; P < .001) 🤩 ascopubs.org/doi/abs/10.120…

A second example of a DDR factor that associates with Okazaki fragment. 53BP1 interacts with the RNA primer from Okazaki fragments to support their processing during unperturbed DNA replication biorxiv.org/content/10.110…

Daniel Levi Ludmir, un médico asesinado en Israel. BDE.

Thrilled to share our latest study in Molecular Cell ! We discovered a novel compound that can detect, track and isolate viable senescent cells!! Big collaborative study including our Bartek Lab led by Gorgoulis group 1/2 authors.elsevier.com/c/1ht953vVUPNy…

Is p53 the next "undruggable" target to become druggable in cancer? For more, read this recent Cancer Discovery paper by Keelan Guiley & Kevan Shokat: A Small Molecule Reacts with the #p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability doi.org/10.1158/2159-8… #Targets23 UC San Francisco

Now out in JNCI! Use of the prostate biopsy Decipher genomic classifier test is associated with increased likelihood of conservative management of localized prostate cancer. Zaorsky et al. University Hospitals #pcsm #prostatecancer Read more here: doi.org/10.1093/jncics…

The ESMO - Eur. Oncology LBAs are out And a wow for PEMBRO/EV (Presidential) OS 31.5 vs 16.1 months (HR 0.45) PFS 12.5 vs 6.3 months (HR 0.47) P<0.00001 A historic change for 1L mUC since Von Der Maase JCO 2000 Tom Powles #ESMO23 OncoAlert

Our paper is out, Bravo and thanks to all the contributors!!👏👏 Take home: after DSB induction, gH2AX domains self-segregate to form a new chromatin compartment, in which some DDR genes also physically relocate to potentiate their expression. rdcu.be/doT6W

EMBARK published 🚨 NEJM #prostatecancer Pts w/ high-risk biochemical recurrence after XRT or surgery (n=1068) 5-yr met-free survival 71% - Lupron 80% - Enzalutamide 87% - Enza+lupron Major work establishing high-risk BCR & enza as monotherapy Link: tinyurl.com/f8rjjfa2

🆕 insights from the STAMPEDE trial presented #ESMO2023: 5️⃣-year incidence of upper urinary tract obstruction significantly ⬇️ with prostate RT in all men with mHSPC❗️ #ProstateCancer Chris Parker Nick James also on @Prof-Nick-James.bsky.social ESMO - Eur. Oncology OncoAlert ESTRO ASTRO

#ESMO23 Presidential session talk by #OliverSartor 👉 177Lu-PSMA-617 shows superiority to ARPI change in taxane-naïve pts w/ mCRPC #prostatecancer : Lutetium vs ARPI change 👉57% reduction in risk of progression 👇 OncoAlert UroToday.com Uromigos APCC

🚨 The Clinical Genetics Service at Memorial Sloan Kettering Cancer Center is hosting a patient symposium focusing on #ATM & #PALB2 🧬 🗓️ 11/14 ⌚️6:30 PM ET 📍Zoom All are cordially invited. Please share with your colleagues & patients! Register: meetmsk.zoom.us/webinar/regist…

#TumorBoardTuesday Brian Rini, MD Hans Hammers Matt Galsky Dan George Enrique Grande Nazli Dizman Cristiane D Bergerot Joshua Meeks Misha Beltran @morr316 Andrey Soares Thomas Hope Karine Tawagi MD @gulleyj1 Simon C Minas Economides, MD @ASanchez_UroOnc Jason Lewis Radiochem MSK Christopher Sweeney, MBBS @AminaZoubeidi Mike Pishvaian Johnathan Ebben MD, PhD Shilpa Gupta Neeraj Agarwal, MD, FASCO Rafee Talukder Xiao Wei, MD Tom Powles Samir Zaidi, MD, PhD Salma Kaochar Renee Maria Saliby Pedro C Barata, MD MSc FACP silke gillessen Ali Khaki Leonard Appleman André P. Fay Albert Jang, MD Yüksel Ürün Salomon Tendler Alan Tan Christophe Massard Mark C. Markowski Sylvan Baca MD PhD (Hiring!) Dr. Jones Nauseef Abhishek Chakraborty BC Andrew Armstrong AttardLab 8/19 #TumorBoardTuesday #ASCO23 #GU23 👨🏽‍🏫Mini Tweetorial 5👨🏽‍🏫 ✨TALAPRO-2 📍Cohort B included only HRR-mutated mCRPC 📍HRR gene alterations assessed: BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12 📚Neeraj Agarwal, MD, FASCO Arun Azad pubmed.ncbi.nlm.nih.gov/37285865/

Chromoscope is now published in @NatureMethods! Chromoscope is open-source and well-documented. Try it out on example/your data and share your feedback! SEHI L’YI Peter J Park Nils Gehlenborg trevor manz chromoscope #CancerGenomics

Very excited to share our latest work, published in Science Translational Medicine today, and making it to the cover! (1/x) Yale Radiation Oncology Residency Yale Cancer Center Saltzman Lab science.org/doi/abs/10.112…

A monumental work by many in my lab and Protein & Crystallography Facility , and another wonderful collaboration with Pietro Pichierri 🇮🇹🇪🇺 @[email protected] and his team! A double-ring of human RAD52 remodels replication forks restricting fork reversal biorxiv.org/content/10.110… Morteza Nick Schnicker Lokesh Gakhar

The Powell lab is hiring! Two funded post-doctoral positions. Come join us in NY Memorial Sloan Kettering Cancer Center! Simon Powell shorturl.at/bzFPY

POLQ and Pol Delta are working together to synthesize DNA during DSB repair via MMEJ. 👏👏👏 Also explains how POLQ seals post-replicative ssDNA gaps on the lagging strand during replication, which I and others have previously observed. nature.com/articles/s4158…

Delighted to share the results of #PACE B trial, published in NEJM today 5 fraction SBRT is non inferior to CRT! nejm.org/media/doi/full… Alison Tree 💙 Follow us on Bluesky @ICR-CTSU Prof Emma Hall The Royal Marsden NHS Foundation Trust Dr. Andrew Loblaw Clive Peedell ST Prof Joe O'Sullivan Prof Suneil Jain

Yes. Thanks for the genius-level insight. I have a genetic terminal disease. Had I been born 10 years earlier, I’d likely be dead. Fortunately a pharmaceutical company solved the problem with a couple daily pills and now I get to live.